GF Fund Management’s Anavex Life Sciences AVXL Stock Holding History

GF Fund Management’s Portfolio AVXL Stock Details AVXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$4.32K	Buy	2,137 +173	+9%	+$478	﹤0.01%	581
2026 Q2	$5.09K	Sell	1,964 -30	-2%	-$89	﹤0.01%	570
2026 Q1	$6.12K	Buy	1,994 +239	+14%	+$1.04K	﹤0.01%	595
2025 Q4	$6.25K	Sell	1,755 -93	-5%	-$570	﹤0.01%	609
2025 Q3	$16.4K	Sell	1,848 -323	-15%	-$3.28K	﹤0.01%	512
2025 Q2	$20K	Hold	2,171	–	–	﹤0.01%	505
2025 Q1	$18.6K	Buy	2,171 +391	+22%	+$3.69K	﹤0.01%	509
2024 Q4	$19.1K	Buy	+1,780	New	+$13.7K	﹤0.01%	475

Other funds holding AVXL

Apella Capital West Hartford, Connecticut $7.88B AUM 10.78% 1-Year Est. Return

PVG Asset Management Golden, Colorado $147M AUM 52.72% 1-Year Est. Return

LexAurum Advisors Overland Park, Kansas $893M AUM

Sheets Smith Wealth Management Winston-Salem, North Carolina $958M AUM 21.88% 1-Year Est. Return

Forum Financial Management Lombard, Illinois $7.7B AUM 11.59% 1-Year Est. Return

VestGen Advisors Inverness, Illinois $3.25B AUM 30.95% 1-Year Est. Return

Foster Victor Wealth Advisors Greenville, South Carolina $2.02B AUM 20.94% 1-Year Est. Return

China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return

Atria Investments Charlotte, North Carolina $10.3B AUM 19.62% 1-Year Est. Return

Anchyra Partners Atlanta, Georgia $477M AUM 34.33% 1-Year Est. Return

GF Fund Management's AVXL Position: Q3 2026 in Review

GF Fund Management increased its Anavex Life Sciences (AVXL) stake by 8.8% in Q3 2026, buying an estimated $478 and bringing the position to 2,137 shares worth $4.32K. The position accounts for ﹤0.01% of the portfolio, ranked #581.

GF Fund Management first reported a position in AVXL in Q4 2024 and has held it in 8 quarters since. The position peaked at $20K in Q2 2025. 32 funds tracked by Wall St. Rank hold AVXL as of Q3 2026.

GF Fund Management held 2,137 shares of Anavex Life Sciences worth $4.32K as of Q3 2026.
GF Fund Management bought 173 Anavex Life Sciences shares in Q3 2026, an estimated $478.
Anavex Life Sciences made up ﹤0.01% of GF Fund Management's portfolio in Q3 2026, its #581 holding.
GF Fund Management first reported a position in Anavex Life Sciences in Q4 2024 and has held it in 8 quarters since.
GF Fund Management's Anavex Life Sciences position peaked at $20K in Q2 2025.
32 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q3 2026.

Based on GF Fund Management's 13F filing for Q3 2026, filed 26 Oct 2026.